Can a simple scan predict lung cancer treatment success?

NCT ID NCT03832348

Completed Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 40 people with advanced non-small cell lung cancer who were starting treatment with the drug pembrolizumab. Researchers used special PET scans after each of the first three doses to see how the cancer's metabolism changed. The goal was to find out if early scan results could predict whether the treatment would work after three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab
What this could lead to: If successful, this could help doctors use early PET scans to quickly tell if pembrolizumab is working for lung cancer patients.
What could go wrong: This is a small, completed observational study with only 40 participants. It does not test a new treatment, so it may not change how doctors treat lung cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CHU

Rouen, 76000, France
Centre Henri Becquerel

Rouen, 76000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.